scholarly journals Endoscopic Detection of Small Bowel Dysplasia and Adenocarcinoma in Crohn’s Disease: A Prospective Cohort-Study in High-Risk Patients

2016 ◽  
Vol 11 (1) ◽  
pp. 47-52 ◽  
Author(s):  
M. Simon ◽  
J. Cosnes ◽  
J. M. Gornet ◽  
P. Seksik ◽  
C. Stefanescu ◽  
...  
Keyword(s):  
Cohort Study ◽  
Crohn’S Disease ◽  
High Risk ◽  
Small Bowel ◽  
Crohn's Disease ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
High Risk Patients ◽  
Risk Patients

scholarly journals Serum tenascin-C predicts resistance to steroid combination therapy in high-risk Kawasaki disease: A multicenter prospective cohort study

2021 ◽  
Author(s):  
Yukako Yoshikane ◽  
Yoshiaki Okuma ◽  
Tatsuki Miyamoto ◽  
Junichi Hashimoto ◽  
Ryuji Fukazawa ◽  
...  
Keyword(s):  
Cohort Study ◽  
High Risk ◽  
Combination Therapy ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Initial Treatment ◽  
Initial Therapy ◽  
High Risk Patients ◽  
Tenascin C ◽  
Risk Patients

Abstract Background: Tenascin-C (TN-C) is an extracellular matrix glycoprotein related to tissue inflammation. Our previous retrospective study conducted in 2016 revealed that the serum tenascin-C level was higher in patients with Kawasaki disease (KD) who were resistant to intravenous immunoglobulin (IVIG) and developed coronary artery lesions (CALs). The present study is a prospective cohort study to assess if the serum level of tenascin-C could be used as a novel biomarker to predict the risk of resistance to initial treatment for high-risk patients. Methods: A total of 380 KD patients were registered and provided serum samples for tenascin-C measurement before commencing their initial treatment. Patients who did not meet the inclusion criteria were excluded from analysis; of the 181 remaining subjects, there were 144 low-risk patients (Kobayashi score: ≤4 points) and 37 high-risk patients (Kobayashi score: ≥5 points). The initial treatments for low-risk patients and high-risk patients were conventional therapy (IVIG with aspirin) and prednisolone combination therapy, respectively. The patient clinical and laboratory data, including the serum tenascin-C level, were compared between initial treatment responders and non-responders. Results: In the low-risk patients, there was no significant difference in the median levels of serum tenascin-C between the initial therapy responders and non-responders. However, in the high-risk patients, the median serum tenascin-C level in initial therapy non-responders was significantly higher than that in initial therapy responders (175.8 ng/ml vs 117.6 ng/ml). Conclusions: Serum tenascin-C could be a biomarker for predicting the risk of high-risk patients being non-responsive to steroid combination therapy. Trial registration: This study was a prospective cohort study. It was approved by the ethics committee of each institute and performed in accordance with the Declaration of Helsinki.

scholarly journals Serum tenascin-C predicts resistance to steroid combination therapy in high-risk Kawasaki disease: a multicenter prospective cohort study

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Yukako Yoshikane ◽  
Yoshiaki Okuma ◽  
Tatsuki Miyamoto ◽  
Junichi Hashimoto ◽  
Ryuji Fukazawa ◽  
...  
Keyword(s):  
Cohort Study ◽  
High Risk ◽  
Combination Therapy ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Initial Treatment ◽  
Initial Therapy ◽  
High Risk Patients ◽  
Tenascin C ◽  
Risk Patients

Abstract Background Tenascin-C (TN-C) is an extracellular matrix glycoprotein related to tissue inflammation. Our previous retrospective study conducted in 2016 revealed that the serum tenascin-C level was higher in patients with Kawasaki disease (KD) who were resistant to intravenous immunoglobulin (IVIG) and developed coronary artery lesions (CALs). The present study is a prospective cohort study to assess if the serum level of tenascin-C could be used as a novel biomarker to predict the risk of resistance to initial treatment for high-risk patients. Methods A total of 380 KD patients were registered and provided serum samples for tenascin-C measurement before commencing their initial treatment. Patients who did not meet the inclusion criteria were excluded from analysis; of the 181 remaining subjects, there were 144 low-risk patients (Kobayashi score: ≤4 points) and 37 high-risk patients (Kobayashi score: ≥5 points). The initial treatments for low-risk patients and high-risk patients were conventional therapy (IVIG with aspirin) and prednisolone combination therapy, respectively. The patient clinical and laboratory data, including the serum tenascin-C level, were compared between initial treatment responders and non-responders. Results In the low-risk patients, there was no significant difference in the median levels of serum tenascin-C between the initial therapy responders and non-responders. However, in the high-risk patients, the median serum tenascin-C level in initial therapy non-responders was significantly higher than that in initial therapy responders (175.8 ng/ml vs 117.6 ng/ml). Conclusions Serum tenascin-C could be a biomarker for predicting the risk of high-risk patients being non-responsive to steroid combination therapy. Trial registration This study was a prospective cohort study. It was approved by the ethics committee of each institute and performed in accordance with the Declaration of Helsinki.

scholarly journals Improving Utilization of Aspirin for Prevention of Preeclampsia in a High-Risk Urban Cohort: A Prospective Cohort Study

2020 ◽  
Author(s):  
Rupsa C. Boelig ◽  
Mariam Wanees ◽  
Tingting Zhan ◽  
Vincenzo Berghella ◽  
Amanda Roman
Keyword(s):  
Cohort Study ◽  
Preterm Birth ◽  
High Risk ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Screening Tool ◽  
Adjusted Risk ◽  
High Risk Patients ◽  
Risk Patients ◽  
One Year

Objective This study aimed to evaluate the utilization of aspirin for preeclampsia prevention before and after implementation of a screening tool during nuchal translucency (NT) ultrasound. Study Design One-year prospective cohort study of patients at high risk for preeclampsia after the implementation of a screening tool (postscreen) administered to all patients at check in for NT (11–13 weeks) ultrasound. Prospective cohort was compared with one-year retrospective cohort (prescreen) the year prior (2017). All patients who presented for NT ultrasound in both cohorts were evaluated for the presence of one or more risk factor for preeclampsia with screening tool collected prospectively and chart review retrospectively. Provider recommendation for aspirin determined by documentation in prenatal record. Primary outcome was rate of provider recommendation for aspirin pre versus post screening tool, compared by Chi-square test and adjusted for potential confounders with multiple regression analysis. Results Pre- (n = 156) and postscreen (n = 136) cohorts were similar except for race and multifetal gestation. Prescreen, rate of provider recommendation for aspirin was 74%. Of those with prior preeclampsia, 96% were recommended aspirin, compared with 64% of patients with other risk factors (p < 0.001). Postscreen, provider recommendation of aspirin improved to 95% (p < 0.001). Rate of preeclampsia/gestational hypertension were similar between cohorts; however, there was a reduced adjusted risk in overall preterm birth <37 weeks (adjusted odds ratio [aOR] = 0.50 [0.25–0.99]) and preterm birth <34 weeks (aOR = 0.33 [0.13–0.88]) postscreening tool implementation. Conclusion Prior to implementation of a simple screening questionnaire, approximately 25% of high risk patients did not receive the recommendation of aspirin for preeclampsia prevention. High-risk patients who lack a history of preeclampsia were less likely to be advised of aspirin prophylaxis. Use of a simple universal screening tool at time of NT ultrasound significantly improved utilization of aspirin for preeclampsia prevention and may improve patient outcomes. Key Points

scholarly journals Serum tenascin-C predicts resistance to steroid combination therapy in high-risk Kawasaki disease: A multicenter prospective cohort study

2020 ◽  
Author(s):  
YUKAKO YOSHIKANE ◽  
YOSHIAKI OKUMA ◽  
TATSUKI MIYAMOTO ◽  
JUNICHI HASHIMOTO ◽  
RYUJI FUKAZAWA ◽  
...  
Keyword(s):  
Cohort Study ◽  
High Risk ◽  
Kawasaki Disease ◽  
Combination Therapy ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Initial Treatment ◽  
Low Risk ◽  
High Risk Patients ◽  
Risk Patients

Abstract Background Tenascin-C (TN-C) is an extracellular matrix glycoprotein related to tissue inflammation. Our previous retrospective study conducted in 2016 revealed that the serum TN-C level was higher in patients with Kawasaki disease (KD) who were resistant to intravenous immunoglobulin (IVIG) and developed coronary artery lesions (CALs). The present study is a prospective cohort study to assess if the serum level of TN-C could be used as a novel biomarker to predict the risk of resistance to initial treatment for high-risk patients. Methods A total of 380 KD patients were registered and provided serum samples for TN-C measurement before commencing their initial treatment. Patients who did not meet the inclusion criteria were excluded from analysis; of the 181 remaining subjects, there were 144 low-risk patients (Kobayashi score: ≤4 points) and 37 high-risk patients (Kobayashi score: ≥5 points). The initial treatments for low-risk patients and high-risk patients were conventional therapy (IVIG with aspirin) and prednisolone combination therapy, respectively. The patient clinical and laboratory data, including the serum TN-C level, were compared between responders and non-responders to initial treatment. Results In the low-risk patients, there was no significant difference in the median levels of serum TN-C between responders and non-responders to initial therapy. However, in the high-risk patients, the median serum TN-C level in non-responders was significantly higher than that in responders (175.8 ng/ml vs 117.6 ng/ml). Conclusions Serum TN-C could be a biomarker for predicting the risk of high-risk patients being non-responsive to steroid combination therapy. Trial registration: This study was a prospective cohort study. It had been performed in accordance with the Declaration of Helsinki and had been approved by the ethics committee in each institute.

Sign in / Sign up

Export Citation Format

Share Document